AVROBIO receives Nasdaq deficiency notice for minimum bid price non-compliance

Tectonic Therapeutic, Inc.

On Oct 4, 2022, Nasdaq notified AVROBIO that its common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.
Company has 180 calendar days, until April 3, 2023, to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant by deadline, AVROBIO may be eligible for additional 180 days by transferring to Nasdaq Capital Market.
Company intends to monitor bid price and consider options including reverse stock split to cure deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.